Striking the right notes to treat complex diseases.
Advancing novel bispecific antibodies and antibody-drug conjugates to treat cancer.
A different approach to antibody and ADC engineering.
Leveraging our technology, unique insights and capabilities to develop bispecifics and ADCs with superior profiles.
Advancing programs to improve current therapies and better serve patients.
We are developing programs to address specific issues in currently available therapies and overcome major hurdles in novel classes of molecules.
A team of experts from across the world.
Our team’s expertise and insights position us well to usher in a new wave of novel bispecific antibody and ADC therapies.